UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I Study

Journal of clinical oncology, 2005-08, Vol.23 (24), p.5464-5473

2005

Volltextzugriff (PDF)

Review of epidermal growth factor receptor biology

International journal of radiation oncology, biology, physics, 2004-01, Vol.59 (2), p.S21-S26

Herbst, Roy S

2004

Volltextzugriff (PDF)

Development of Biologic Markers of Response and Assessment of Antiangiogenic Activity in a Clinical Trial of Human Recombinant Endostatin

Journal of clinical oncology, 2002-09, Vol.20 (18), p.3804-3814

2002

Volltextzugriff (PDF)

Non‐Small Cell Lung Cancer and Antiangiogenic Therapy: What Can Be Expected of Bevacizumab?

The oncologist (Dayton, Ohio), 2004-01, Vol.9 (S1), p.19-26

2004

Volltextzugriff (PDF)

A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2001-12, Vol.34 (3), p.427-432

2001

Volltextzugriff (PDF)

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2005-09, Vol.23 (25), p.5892-5899

2005

Volltextzugriff (PDF)

Lung Cancer: New Understandings and Therapies

1, 2021

Volltextzugriff (PDF)

Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications

Journal of clinical oncology, 2005-05, Vol.23 (14), p.3243-3256

2005

Volltextzugriff (PDF)

Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy

Cancer, 2002-03, Vol.94 (5), p.1593-1611

2002

Volltextzugriff (PDF)

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2004-06, Vol.22 (11), p.2184-2191

2004

Volltextzugriff (PDF)

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

Journal of clinical oncology, 2005-09, Vol.23 (25), p.5900-5909

2005

Volltextzugriff (PDF)

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Journal of clinical oncology, 2004-03, Vol.22 (5), p.785-794

2004

Volltextzugriff (PDF)

Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck

Journal of clinical oncology, 2005-08, Vol.23 (24), p.5578-5587

2005

Volltextzugriff (PDF)

Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results

Journal of clinical oncology, 2005-08, Vol.23 (24), p.5474-5483

2005

Volltextzugriff (PDF)

Innovative Clinical Trials: The LUNG-MAP Study

Clinical pharmacology and therapeutics, 2015-05, Vol.97 (5), p.488-491

2015

Volltextzugriff (PDF)

Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials

Journal of clinical oncology, 2005-11, Vol.23 (31), p.8081-8092

2005

Volltextzugriff (PDF)

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

JAMA : the journal of the American Medical Association, 2003-10, Vol.290 (16), p.2149

2003

Volltextzugriff (PDF)

Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2005-04, Vol.23 (11), p.2544-2555

2005

Volltextzugriff (PDF)

[18F]Fluorodeoxyglucose Uptake by Positron Emission Tomography Predicts Outcome of Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2005-02, Vol.23 (6), p.1136-1143

2005

Volltextzugriff (PDF)

Interobserver and Intraobserver Variability in Measurement of Non–Small-Cell Carcinoma Lung Lesions: Implications for Assessment of Tumor Response

Journal of clinical oncology, 2003-07, Vol.21 (13), p.2574-2582

2003

Volltextzugriff (PDF)

Mode of action of docetaxel – a basis for combination with novel anticancer agents

Cancer treatment reviews, 2003-10, Vol.29 (5), p.407-415

2003

Volltextzugriff (PDF)

Phase I/IIa Study of Cetuximab With Gemcitabine Plus Carboplatin in Patients With Chemotherapy-Naïve Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2005-12, Vol.23 (36), p.9089-9096

2005

Volltextzugriff (PDF)

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial

Journal of clinical oncology, 2002-09, Vol.20 (18), p.3815-3825

2002

Volltextzugriff (PDF)

Thalidomide, cyclooxygenase-2, and angiogenesis: potential for therapy

Clinical cancer research, 2001-11, Vol.7 (11), p.3311-3313

2001

Volltextzugriff (PDF)

Erlotinib (Tarceva): an update on the clinical trial program

Seminars in oncology, 2003-06, Vol.30, p.34-46

Herbst, Roy S

2003

Volltextzugriff (PDF)

1 – 25 von 123

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(118)
Mit Volltextzugriff
(113)

Publikationsform

Artikel
(122)
Bücher
(1)

Sprache

Englisch
(123)

Erscheinungsjahr

n.n

Thema

Science & Technology
(123)
Life Sciences & Biomedicine
(102)
Humans
(86)
Oncology
(79)
Biological And Medical Sciences
(62)
Medical Sciences
(57)
Female
(46)
Male
(45)
Lung Neoplasms - Drug Therapy
(43)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(40)
Middle Aged
(36)
Adult
(34)
Aged
(33)
Antineoplastic Agents
(31)
Pharmacology. Drug Treatments
(30)
Animals
(28)
Lung Neoplasms - Pathology
(26)
Chemotherapy
(24)
Treatment Outcome
(23)
Tumors
(23)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Pharmacodynamic Measure of Response After Acute Dosing of AG-013736, an Oral Angiogenesis Inhibitor, in Patients With Advanced Solid Tumors: Results From a Phase I Study

Review of epidermal growth factor receptor biology

Development of Biologic Markers of Response and Assessment of Antiangiogenic Activity in a Clinical Trial of Human Recombinant Endostatin

Non‐Small Cell Lung Cancer and Antiangiogenic Therapy: What Can Be Expected of Bevacizumab?

A phase II study of STEALTH cisplatin (SPI-77) in patients with advanced non-small cell lung cancer

TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung Cancer

Lung Cancer: New Understandings and Therapies

Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications

Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy

Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer

Mutations in the Epidermal Growth Factor Receptor and in KRAS Are Predictive and Prognostic Indicators in Patients With Non–Small-Cell Lung Cancer Treated With Chemotherapy Alone and in Combination With Erlotinib

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck

Phase I Trial of the Oral Antiangiogenesis Agent AG-013736 in Patients With Advanced Solid Tumors: Pharmacokinetic and Clinical Results

Innovative Clinical Trials: The LUNG-MAP Study

Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

Phase I/II Trial Evaluating the Anti-Vascular Endothelial Growth Factor Monoclonal Antibody Bevacizumab in Combination With the HER-1/Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib for Patients With Recurrent Non–Small-Cell Lung Cancer

[18F]Fluorodeoxyglucose Uptake by Positron Emission Tomography Predicts Outcome of Non–Small-Cell Lung Cancer

Interobserver and Intraobserver Variability in Measurement of Non–Small-Cell Carcinoma Lung Lesions: Implications for Assessment of Tumor Response

Mode of action of docetaxel – a basis for combination with novel anticancer agents

Phase I/IIa Study of Cetuximab With Gemcitabine Plus Carboplatin in Patients With Chemotherapy-Naïve Advanced Non–Small-Cell Lung Cancer

Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Is Generally Well-Tolerated and Has Activity in Non–Small-Cell Lung Cancer and Other Solid Tumors: Results of a Phase I Trial

Thalidomide, cyclooxygenase-2, and angiogenesis: potential for therapy

Erlotinib (Tarceva): an update on the clinical trial program

Suchergebnisse filtern